Vesalius Biocapital leads €50m round for CatalYm

Novartis Venture Fund (NVF), Wachstumsfonds Bayern and Coparion also took part in the round, alongside Forbion and BioGeneration Ventures, both of which supported the founding of the company in 2016.

Following the round, representatives from Vesalius Biocapital, NVF and Wachstumsfonds Bayern will join CatalYm's management board.

The new funding is intended to support clinical development of the company's cancer treatment therapies.

Vesalius invested via its third flagship fund, which held a final close in June 2019 on €120m. The fund makes investments in later-stage life sciences companies based in Europe.

Previous funding
BioGeneration and Forbion invested in CatalYm in 2016, providing capital to launch the company and its research. BioGeneration invested via its third fund, which held a final close in October 2017 on €82m.

Company
Founded in 2020 and based in Planegg, CatalYm develops monoclonal antibodies that it claims enhance the effective infiltration of immune cells into the micro-environment of cold tumours. Its therapies can be used for the treatment of cancer. The antibody CTL-002 is to be developed as a monotherapy, entering clinical development in December 2020.

People
CatalYm – Manfred Rüdiger
Versalis Biopharma – Marc Lohrmann (manging partner).
Forbion – Holger Reithinger (general partner); Rogier Rooswinkel (partner).

Advisers
Company – Baker McKenzie (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Venture
• Germany